Intensive Care Unit (ICU) PatientsInterOncoReaNCT06993987
Study of Interactions Between Oncologists and Resuscitators to Optimize Decision Making for Admission of Patients With Metastatic Solid Cancer to the ICU (InterOncoRea)
An observational study of Intensive Care Unit (ICU) Patients and Metastatic Cancer, run by University Hospital, Brest at 1 site in France.
Trial summary
The aim of our study is to optimise the interaction between oncologists and resuscitators to improve decision-making regarding the admission of patients with metastatic solid cancers to the ICU. The study is structured into two successive stages. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Intensive Care Unit (ICU) Patients, Metastatic Cancer
- What is being tested?
- Descriptive analysis
- How many people
- 139 participants
- Where
- 1 siteFrance
- Study dates
- 1 Mar 2025to 31 Oct 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: ICU patients with metastatic solid cancer
Who may be able to join
- Major patient hospitalized in medical or surgical intensive care with metastatic solid cancer, whatever the primary site and whatever the reason for admission to the intensive care unit
- Start of stay in intensive care must be between June 1, 2023 and June 1, 2024.
Who cannot join
- Patient objecting to data processing
- The patient is under legal protection (e.g. guardianship or curatorship)
- A patient with multiple synchronous cancers
- Diagnosis of metastatic cancer during stay in intensive care unit intensive care unit
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of Interactions Between Oncologists and Resuscitators to Optimize Decision Making for Admission of Patients With Metastatic Solid Cancer to the ICU
The aim of our study is to optimise the interaction between oncologists and resuscitators to improve decision-making regarding the admission of patients with metastatic solid cancers to the ICU.
The study is structured into two successive stages. The first stage involves a retrospective descriptive analysis of patients with metastatic solid cancer admitted to the ICU, to enable comparison with centres that have already documented this subject.
The second stage involves personalised interviews with medical staff working in both the oncology department and the intensive care unit.
Read the detailed description
In the vast majority of cases, there is no cure for metastatic solid cancer. As a result, the question of end of life is very often present.
End of life may be linked to the aggressiveness of the disease, to therapeutic damage, but also to an independent acute event that may occur during the course of oncology care.
This explains why the question of resuscitation management comes into play in the care of our oncology patients.
The literature shows that one in 7 patients admitted to intensive care in Europe has a history of cancer, and that 5 to 10% of cancer patients will require intensive care during their course of treatment.
The therapeutic advances brought about by immunotherapy in the first instance, followed by targeted therapies in a second phase, have considerably altered the prognosis of patients with solid cancers, including the most aggressive cancers.
However, given the poor prognosis of these diseases, having metastatic cancer continues to hinder a patient's possible admission to the intensive care unit.
The second most common reason for refusing admission to the ICU is having cancer.
Yet the post-ICU mortality rate for cancer patients is identical to that of the entire ICU patient group.
Various scores have been used to determine the 'right' criteria for ICU admission for patients with metastatic solid cancers.
Nevertheless, nothing appears to be more effective than communication between oncologists and intensive care physicians, particularly since the prognosis of patients with advanced cancers is still a subject of interdisciplinary discussion.
Various scores have attempted to establish the 'right' criteria for admitting patients with metastatic solid cancers to intensive care.
However, nothing appears more effective than discussions between oncologists and resuscitators, particularly given that the prognosis of patients with advanced cancers is still a topic of interdisciplinary debate.
Indeed, the decision to admit a patient with metastatic cancer to an intensive care unit appears to raise ethical, medical and organisational issues.
Bearing this in mind, and given the numerous studies already conducted in this area, we thought it would be interesting to examine the relationship between oncology and intensive care units.
To study the interactions between intensive care physicians and oncologists and identify areas for improvement in patient care, we devised a two-stage approach.
First, we conducted personalised semi-structured interviews with doctors from the medical oncology department (oncologists, organ specialists and general practitioners) and doctors from the intensive care unit. This allowed us to identify the obstacles that each speciality faces when admitting a patient to the intensive care unit. This would enable us to deduce the elements essential for reaching an agreement on admitting a patient to the intensive care unit (Stage 1).
Secondly, we will review practices at Brest University Hospital (and possibly other centres that might be interested in our work) and compare them with data in the literature to see if our decisions are similar to those made in other centres that have already documented the subject (Stage 2).
- Being tested
- Descriptive analysis
- Keywords
- Metastatic cancer, Intensive care, Admission of a patient with metastatic solid cancer to intensive care, Metastatic solid cancer and intensive care, Communication between intensivists and oncologists, Reason for hospitalization for patients with metastatic solid cancer, Survival for patients with metastatic cancer after admission to the intensive care unit, Metastatic solid cancer
- Medical subject headings
- Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Descriptive analysisOther
The descriptive analysis of qualitative variables (reason for admission) will be carried out in the form of frequencies and percentages. Quantitative variables will be described in terms of averages, medians or standard deviations, as required.
| Study group | Role | What they receive |
|---|---|---|
| Patients with metastatic solid cancer admitted to the ICU | Not described Receives: Other: Descriptive analysis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of reason for admission to intensive care unit
Analysis of the reason for admission to intensive care unit
Measured: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Secondary outcomes (3)
Protective and risk factors
Protective and risk factors for returning home within 3 months
Measured: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Survival at 1 month and 3 months
Survival at 1 month and 3 months from admission to intensive care unit
Measured: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Risk factors for survival in intensive care
Measured: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2025
- Study start1 Mar 2025
- Primary completion31 Oct 2025 (estimated)
- Study completion31 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Intensive Care Unit (ICU) PatientsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 139 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06993987
- Sponsor's protocol ID
- 29BRC25.0045 - InterOncoRea
- Acronym
- InterOncoRea
- Status last verified
- Mar 2025
- First submitted
- 20 May 2025
- Last updated
- 29 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected data that underlie results in a publication
Publications
Iapichino G, Corbella D, Minelli C, Mills GH, Artigas A, Edbooke DL, Pezzi A, Kesecioglu J, Patroniti N, Baras M, Sprung CL. Reasons for refusal of admission to intensive care and impact on mortality. Intensive Care Med. 2010 Oct;36(10):1772-1779. doi: 10.1007/s00134-010-1933-2. Epub 2010 Jun 9.
PubMed 20533023Robert R, Reignier J, Tournoux-Facon C, Boulain T, Lesieur O, Gissot V, Souday V, Hamrouni M, Chapon C, Gouello JP; Association des Reanimateurs du Centre Ouest Group. Refusal of intensive care unit admission due to a full unit: impact on mortality. Am J Respir Crit Care Med. 2012 May 15;185(10):1081-7. doi: 10.1164/rccm.201104-0729OC. Epub 2012 Feb 16.
PubMed 22345582Padhi S, Shrestha P, Alamgeer M, Stevanovic A, Karikios D, Rajamani A, Subramaniam A. Oncology and intensive care doctors' perception of intensive care admission of cancer patients: A cross-sectional national survey. Aust Crit Care. 2024 Jul;37(4):520-529. doi: 10.1016/j.aucc.2023.12.005. Epub 2024 Feb 12.
PubMed 38350752Nassar AP Jr, Dettino ALA, Amendola CP, Dos Santos RA, Forte DN, Caruso P. Oncologists' and Intensivists' Attitudes Toward the Care of Critically Ill Patients with Cancer. J Intensive Care Med. 2019 Oct;34(10):811-817. doi: 10.1177/0885066617716105. Epub 2017 Jul 5.
PubMed 28675982Toffart AC, Gonzalez F, Hamidfar-Roy R, Darrason M. [ICU admission for cancer patients with respiratory failure: An ethical dilemma]. Rev Mal Respir. 2023 Oct;40(8):692-699. doi: 10.1016/j.rmr.2023.07.003. Epub 2023 Aug 31. French.
PubMed 37659881Borcoman E, Dupont A, Mariotte E, Doucet L, Joseph A, Chermak A, Valade S, Resche-Rigon M, Azoulay E, Lemiale V. One-year survival in patients with solid tumours discharged alive from the intensive care unit after unplanned admission: A retrospective study. J Crit Care. 2020 Jun;57:36-41. doi: 10.1016/j.jcrc.2020.01.027. Epub 2020 Jan 30.
PubMed 32032902Gwilliam B, Keeley V, Todd C, Roberts C, Gittins M, Kelly L, Barclay S, Stone P. Prognosticating in patients with advanced cancer--observational study comparing the accuracy of clinicians' and patients' estimates of survival. Ann Oncol. 2013 Feb;24(2):482-488. doi: 10.1093/annonc/mds341. Epub 2012 Oct 1.
PubMed 23028038Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409-436. doi: 10.3322/caac.21731. Epub 2022 Jun 23.
PubMed 35736631Bos MM, Verburg IW, Dumaij I, Stouthard J, Nortier JW, Richel D, van der Zwan EP, de Keizer NF, de Jonge E. Intensive care admission of cancer patients: a comparative analysis. Cancer Med. 2015 Jul;4(7):966-76. doi: 10.1002/cam4.430. Epub 2015 Apr 18.
PubMed 25891471Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison DS. Risk of Critical Illness Among Patients With Solid Cancers: A Population-Based Observational Study. JAMA Oncol. 2015 Nov;1(8):1078-85. doi: 10.1001/jamaoncol.2015.2855.
PubMed 26313462Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13(1):R15. doi: 10.1186/cc7713. Epub 2009 Feb 6.
PubMed 19200368
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Interactions Between Oncologists and Resuscitators to Optimize Decision Making for Admission of Patients With Metastatic Solid Cancer to the ICU
- ClinicalTrials.gov ID
- NCT06993987
- Acronym / sponsor ID
- InterOncoRea / 29BRC25.0045 - InterOncoRea
- Keywords
- Metastatic cancer, Intensive care, Admission of a patient with metastatic solid cancer to intensive care, Metastatic solid cancer and intensive care, Communication between intensivists and oncologists, Reason for hospitalization for patients with metastatic solid cancer, Survival for patients with metastatic cancer after admission to the intensive care unit, Metastatic solid cancer
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 139 participants (estimated)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 1 Mar 2025 (actual)
- Primary completion
- 31 Oct 2025 (estimated)
- Study completion
- 31 Oct 2025 (estimated)
- First posted
- 29 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of our study is to optimise the interaction between oncologists and resuscitators to improve decision-making regarding the admission of patients with metastatic solid cancers to the ICU.
The study is structured into two successive stages. The first stage involves a retrospective descriptive analysis of patients with metastatic solid cancer admitted to the ICU, to enable comparison with centres that have already documented this subject.
The second stage involves personalised interviews with medical staff working in both the oncology department and the intensive care unit.
Detailed description
In the vast majority of cases, there is no cure for metastatic solid cancer. As a result, the question of end of life is very often present.
End of life may be linked to the aggressiveness of the disease, to therapeutic damage, but also to an independent acute event that may occur during the course of oncology care.
This explains why the question of resuscitation management comes into play in the care of our oncology patients.
The literature shows that one in 7 patients admitted to intensive care in Europe has a history of cancer, and that 5 to 10% of cancer patients will require intensive care during their course of treatment.
The therapeutic advances brought about by immunotherapy in the first instance, followed by targeted therapies in a second phase, have considerably altered the prognosis of patients with solid cancers, including the most aggressive cancers.
However, given the poor prognosis of these diseases, having metastatic cancer continues to hinder a patient's possible admission to the intensive care unit.
The second most common reason for refusing admission to the ICU is having cancer.
Yet the post-ICU mortality rate for cancer patients is identical to that of the entire ICU patient group.
Various scores have been used to determine the 'right' criteria for ICU admission for patients with metastatic solid cancers.
Nevertheless, nothing appears to be more effective than communication between oncologists and intensive care physicians, particularly since the prognosis of patients with advanced cancers is still a subject of interdisciplinary discussion.
Various scores have attempted to establish the 'right' criteria for admitting patients with metastatic solid cancers to intensive care.
However, nothing appears more effective than discussions between oncologists and resuscitators, particularly given that the prognosis of patients with advanced cancers is still a topic of interdisciplinary debate.
Indeed, the decision to admit a patient with metastatic cancer to an intensive care unit appears to raise ethical, medical and organisational issues.
Bearing this in mind, and given the numerous studies already conducted in this area, we thought it would be interesting to examine the relationship between oncology and intensive care units.
To study the interactions between intensive care physicians and oncologists and identify areas for improvement in patient care, we devised a two-stage approach.
First, we conducted personalised semi-structured interviews with doctors from the medical oncology department (oncologists, organ specialists and general practitioners) and doctors from the intensive care unit. This allowed us to identify the obstacles that each speciality faces when admitting a patient to the intensive care unit. This would enable us to deduce the elements essential for reaching an agreement on admitting a patient to the intensive care unit (Stage 1).
Secondly, we will review practices at Brest University Hospital (and possibly other centres that might be interested in our work) and compare them with data in the literature to see if our decisions are similar to those made in other centres that have already documented the subject (Stage 2).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with metastatic solid cancer admitted to the ICU | – | Other: Descriptive analysis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- ICU patients with metastatic solid cancer
Key inclusion criteria (2 listed)
- Major patient hospitalized in medical or surgical intensive care with metastatic solid cancer, whatever the primary site and whatever the reason for admission to the intensive care unit
- Start of stay in intensive care must be between June 1, 2023 and June 1, 2024.
Key exclusion criteria (4 listed)
- Patient objecting to data processing
- The patient is under legal protection (e.g. guardianship or curatorship)
- A patient with multiple synchronous cancers
- Diagnosis of metastatic cancer during stay in intensive care unit intensive care unit
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Descriptive analysisThe descriptive analysis of qualitative variables (reason for admission) will be carried out in the form of frequencies and percentages. Quantitative variables will be described in terms of averages, medians or standard deviations, as required. | Other | Patients with metastatic solid cancer admitted to the ICU |
Primary outcome
Frequency of reason for admission to intensive care unit
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Analysis of the reason for admission to intensive care unit
3 secondary outcomes
Protective and risk factors
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Survival at 1 month and 3 months
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Risk factors for survival in intensive care
Time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2025.
- Results publication: PubMed 20533023Iapichino G, Corbella D, Minelli C, Mills GH, Artigas A, Edbooke DL, Pezzi A, Kesecioglu J, Patroniti N, Baras M, Sprung CL. Reasons for refusal of admission to intensive care and impact on mortality. Intensive Care Med. 2010 Oct;36(10):1772-1779. doi: 10.1007/s00134-010-1933-2. Epub 2010 Jun 9.
- Results publication: PubMed 22345582Robert R, Reignier J, Tournoux-Facon C, Boulain T, Lesieur O, Gissot V, Souday V, Hamrouni M, Chapon C, Gouello JP; Association des Reanimateurs du Centre Ouest Group. Refusal of intensive care unit admission due to a full unit: impact on mortality. Am J Respir Crit Care Med. 2012 May 15;185(10):1081-7. doi: 10.1164/rccm.201104-0729OC. Epub 2012 Feb 16.
- Results publication: PubMed 38350752Padhi S, Shrestha P, Alamgeer M, Stevanovic A, Karikios D, Rajamani A, Subramaniam A. Oncology and intensive care doctors' perception of intensive care admission of cancer patients: A cross-sectional national survey. Aust Crit Care. 2024 Jul;37(4):520-529. doi: 10.1016/j.aucc.2023.12.005. Epub 2024 Feb 12.
- Results publication: PubMed 28675982Nassar AP Jr, Dettino ALA, Amendola CP, Dos Santos RA, Forte DN, Caruso P. Oncologists' and Intensivists' Attitudes Toward the Care of Critically Ill Patients with Cancer. J Intensive Care Med. 2019 Oct;34(10):811-817. doi: 10.1177/0885066617716105. Epub 2017 Jul 5.
- Results publication: PubMed 37659881Toffart AC, Gonzalez F, Hamidfar-Roy R, Darrason M. [ICU admission for cancer patients with respiratory failure: An ethical dilemma]. Rev Mal Respir. 2023 Oct;40(8):692-699. doi: 10.1016/j.rmr.2023.07.003. Epub 2023 Aug 31. French.
- Results publication: PubMed 32032902Borcoman E, Dupont A, Mariotte E, Doucet L, Joseph A, Chermak A, Valade S, Resche-Rigon M, Azoulay E, Lemiale V. One-year survival in patients with solid tumours discharged alive from the intensive care unit after unplanned admission: A retrospective study. J Crit Care. 2020 Jun;57:36-41. doi: 10.1016/j.jcrc.2020.01.027. Epub 2020 Jan 30.
- Results publication: PubMed 23028038Gwilliam B, Keeley V, Todd C, Roberts C, Gittins M, Kelly L, Barclay S, Stone P. Prognosticating in patients with advanced cancer--observational study comparing the accuracy of clinicians' and patients' estimates of survival. Ann Oncol. 2013 Feb;24(2):482-488. doi: 10.1093/annonc/mds341. Epub 2012 Oct 1.
- Results publication: PubMed 35736631Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022 Sep;72(5):409-436. doi: 10.3322/caac.21731. Epub 2022 Jun 23.
- Results publication: PubMed 25891471Bos MM, Verburg IW, Dumaij I, Stouthard J, Nortier JW, Richel D, van der Zwan EP, de Keizer NF, de Jonge E. Intensive care admission of cancer patients: a comparative analysis. Cancer Med. 2015 Jul;4(7):966-76. doi: 10.1002/cam4.430. Epub 2015 Apr 18.
- Results publication: PubMed 26313462Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison DS. Risk of Critical Illness Among Patients With Solid Cancers: A Population-Based Observational Study. JAMA Oncol. 2015 Nov;1(8):1078-85. doi: 10.1001/jamaoncol.2015.2855.
- Results publication: PubMed 19200368Taccone FS, Artigas AA, Sprung CL, Moreno R, Sakr Y, Vincent JL. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13(1):R15. doi: 10.1186/cc7713. Epub 2009 Feb 6.
- Individual participant dataSharing planned: Yes. All collected data that underlie results in a publication
Related trials for Intensive Care Unit (ICU) Patients
Active, not recruitingObservational study
Adverse Events During Physical Therapy in Neurocritical ICU Patients
Critical Illness, Brain Injury
Recruiting
Effectiveness of Virtual Reality in Improving Upper Limb Function in Critically Ill Patients
Intensive Care Unit (ICU) Acquired Weakness (ICU - AW), Critical Illness
Not yet recruitingObservational study
Diaphragm Ultrasound and Rapid Shallow Breathing Index for Predicting Extubation Success
Ventilator Weaning, Respiratory Insufficiency
Recruiting
VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit
Venous Congestion
Not yet recruitingObservational study
Cumulative Intra-Abdominal Pressure Burden and Acute Kidney Injury After Emergency Abdominal Surgery
Acute Kidney Injury, Intra-Abdominal Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Intensive Care Unit (ICU) Patients and Metastatic Cancer, run by University Hospital, Brest at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of reason for admission to intensive care unit (time frame: Patients admitted to intensive care between June 1, 2023 and June 1, 2024.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06993987, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2025.